N6AMT2 CRISPR/Cas9 KO Plasmid (h): sc-406341
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- N6AMT2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the N6AMT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: N6AMT2 Antibody (H-3): sc-390240
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
N6AMT2 CRISPR/Cas9 KO Plasmid (h) | sc-406341 | 20 µg | $397.00 |
Overview
EEF1AKMT1 encodes N6AMT2, a lysine methyltransferase that modifies translation-associated factors and contributes to proteostasis by tuning protein synthesis and co-translational quality control. N6AMT2 has been linked to regulation of ribosome function and broader RNA metabolism, connecting it to cellular growth programs and stress-adaptive translational control. Altered methylation of translation machinery can reshape signaling outputs downstream of nutrient sensing and proteotoxic stress, making EEF1AKMT1 relevant to studies of cell cycle progression, apoptosis, and metabolic adaptation. Dysregulation of translation and methyltransferase-dependent control is frequently observed in cancer and neurobiology research contexts, supporting investigation of N6AMT2 in disease-associated phenotypes without implying clinical utility.
N6AMT2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the EEF1AKMT1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the EEF1AKMT1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the EEF1AKMT1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish N6AMT2 protein expression.
This CRISPR knockout system enables efficient generation of EEF1AKMT1-deficient cell models for investigation of N6AMT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting EEF1AKMT1 exon(s) critical for N6AMT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple EEF1AKMT1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by N6AMT2 CRISPR/Cas9 KO Plasmid (h) and N6AMT2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the EEF1AKMT1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by N6AMT2 HDR Plasmid (h) and N6AMT2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by EEF1AKMT1 homology arms to support homology-directed repair at defined EEF1AKMT1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.